Hybrid-designed inhibitors of p38 MAP kinase utilizing N-arylpyridazinones.
Imidazo[1,2-a]pyridyl N-arylpyridazinones were hybridized from the classic pyridinylimidazoles and the more recent dual hydrogen bond acceptors, resulting in a new structural class of selective p38 MAP kinase inhibitors.
Colletti
Steven L
SL
Merck Research Laboratories, Merck & Co., Inc., Rahway, New Jersey 07065, USA. steve_colletti@merck.com
Frie
Jessica L
JL
Dixon
Elizabeth C
EC
Singh
Suresh B
SB
Choi
Bernard K
BK
Scapin
Giovanna
G
Fitzgerald
Catherine E
CE
Kumar
Sanjeev
S
Nichols
Elizabeth A
EA
O'Keefe
Stephen J
SJ
O'Neill
Edward A
EA
Porter
Gene
G
Samuel
Koppara
K
Schmatz
Dennis M
DM
Schwartz
Cheryl D
CD
Shoop
Wesley L
WL
Thompson
Chris M
CM
Thompson
James E
JE
Wang
Ruixiu
R
Woods
Andrea
A
Zaller
Dennis M
DM
Doherty
James B
JB
D000818:Animals; D004791:Enzyme Inhibitors / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D051379:Mice; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors* / Q000737:chemistry; D008958:Models, Molecular; D011724:Pyridazines / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D013329:Structure-Activity Relationship; D048051:p38 Mitogen-Activated Protein Kinases
D004791:Enzyme Inhibitors; D011724:Pyridazines; D020928:Mitogen-Activated Protein Kinases; D048051:p38 Mitogen-Activated Protein Kinases